Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • News and press coverage
    • Stock information
    • Governance
    • Documentation

Product candidates

07 April 2022

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing Timeline

28 Oct 2021 - 29 Oct 2021

Cell UK by Oxford’s Global, London (UK) & Virtual

12 October 2021

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa

15 Oct 2021 - 16 Oct 2021

Mitochondrial Diseases Conference 2021 by Mitocon, Virtual

19 Oct 2021 - 22 Oct 2021

28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Virtual

12 Oct 2021 - 14 Oct 2021

2021 ARM Cell & Gene Meeting on the Mesa, Carlsbad, CA (USA) & Virtual

08 Oct 2021 - 12 Oct 2021

39th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), San Antonio, TX (USA)

06 October 2021

GenSight Biologics Announces the Publication of a Review of Gene Therapy Trials for LHON in International Ophthalmology Clinics

07 Oct 2021

OIS Retina Innovation Summit @ASRS, Austin, TX (USA)

05 Oct 2021 - 06 Oct 2021

2021 Advanced Therapies Congress LIVE, London (UK)

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 14
  • View next 9 articles
© 2022 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page